Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004-2013

Sagara Y., Freedman R. A. , Wong S. M. , Aydogan F. , Nguyen A., Barry W. T. , ...Daha Fazla

BREAST CANCER RESEARCH AND TREATMENT, cilt.166, ss.583-592, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 166 Konu: 2
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1007/s10549-017-4436-9
  • Dergi Adı: BREAST CANCER RESEARCH AND TREATMENT
  • Sayfa Sayıları: ss.583-592

Özet

Breast-conserving surgery (BCS) followed by radiotherapy (RT) with or without endocrine therapy (ET) is a standard treatment option for ductal carcinoma in situ (DCIS). We sought to investigate national patterns in the use of adjuvant therapy after BCS for hormone receptor (HR)-positive DCIS over time.